Advanced search
Publication Cover
Leukemia & Lymphoma Volume 54, 2013 - Issue 7
Submit an article Journal homepage
676
Views
36
CrossRef citations to date
0
Altmetric
Research Articles

Risk of second malignant neoplasms after cyclophosphamide-based chemotherapy with or without radiotherapy for non-Hodgkin lymphoma

Yuanlin XuDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
,
Huaqing WangDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, ChinaCorrespondence[email protected]
,
Shiyong ZhouDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
,
Man YuOntario Cancer Institute/Princess Margaret Hospital, University of Toronto, Toronto, Canada
,
Xianhuo WangDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
,
Kai FuDepartment of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA
,
Zhengzi QianDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
,
Huilai ZhangDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
,
Lihua QiuDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
,
Xianming LiuDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
&
Ping WangDepartment of Lymphoma, Tianjin Medical University Cancer Hospital, Sino-US Center for Lymphoma and Leukemia, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin, China
 show all
Pages 1396-1404 | Received 28 Jul 2012, Accepted 19 Oct 2012, Published online: 26 Nov 2012

Citations (36)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Daniela V. Wenge, Klaus Wethmar, Jan-Henrik Mikesch, Christian Reicherts, Christoph Schliemann, Rolf Mesters, Torsten Kessler, Cyrus Khandanpour, Andrea Kerkhoff, Norbert Schmitz, Wolfgang E. Berdel, Georg Lenz & Matthias Stelljes. (2021) Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy. Leukemia & Lymphoma 62:8, pages 1930-1939.
Read now
Ohad Benjamini, Preetesh Jain, Long Trinh, Wei Qiao, Sara S. Strom, Susan Lerner, Xuemei Wang, Jan Burger, Alessandra Ferrajoli, Hagop Kantarjian, Susan O'Brien, William Wierda, Zeev Estrov & Michael Keating. (2015) Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leukemia & Lymphoma 56:6, pages 1643-1650.
Read now

Articles from other publishers (34)

Zhumei Zhan, Wei Guo, Jia Li, Xin Wan, Jing Guo & Ou Bai. (2023) Clinical features and prognosis of double primary malignant neoplasms in patients with non-hodgkin lymphoma. Discover Oncology 14:1.
Crossref
Yu Cui, Wenxia Ren, Xue Du, Lu Yang & Bangxian Tan. (2023) Research Progress of Multiple Primary Malignancies Associated With Esophageal Cancer. Cancer Control 30, pages 107327482311766.
Crossref
Zhumei Zhan, Wei Guo, Xin Wan & Ou Bai. (2023) Second primary malignancies in non-Hodgkin lymphoma: epidemiology and risk factors. Annals of Hematology 102:2, pages 249-259.
Crossref
Szu-Ying Pan, Chi-Ping Huang & Wen-Chi Chen. (2022) Synchronous/Metachronous Multiple Primary Malignancies: Review of Associated Risk Factors. Diagnostics 12:8, pages 1940.
Crossref
Martin S. Highley, Bart Landuyt, Hans Prenen, Peter G. Harper & Ernst A. De Bruijn. (2022) The Nitrogen Mustards. Pharmacological Reviews 74:3, pages 552-599.
Crossref
Zachary Braunstein, Eric McLaughlinAnjali Mishra & Jonathan E. Brammer. (2022) Cyclophosphamide induces durable molecular and clinical responses in patients with relapsed T-LGL leukemia. Blood Advances 6:8, pages 2685-2687.
Crossref
Daniel Rolf, Gabriele Reinartz, Stephan Rehn, Christopher Kittel & Hans Theodor Eich. (2022) Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma. Cancers 14:4, pages 873.
Crossref
Phuong Vo, Lynn Onstad, Mary E. Flowers & Rainer Storb. (2021) Cancers after HLA-matched related bone marrow transplantation for aplastic anemia. Bone Marrow Transplantation 57:1, pages 83-88.
Crossref
Kathryn A. Culos & Katie S. Gatwood. 2021. Blood and Marrow Transplantation Long Term Management. Blood and Marrow Transplantation Long Term Management 381 392 .
Asle Charles Hesla, Andri Papakonstantinou & Panagiotis Tsagkozis. (2021) Current Status of Management and Outcome for Patients with Ewing Sarcoma. Cancers 13:6, pages 1202.
Crossref
Zhiying Zhang, Ting Pan, Chunrong Liu, Xiaoyun Shan, Zeqiong Xu, Huachang Hong, Hongjun Lin, Jianrong Chen & Hongjie Sun. (2021) Cyclophosphamide induced physiological and biochemical changes in mice with an emphasis on sensitivity analysis. Ecotoxicology and Environmental Safety 211, pages 111889.
Crossref
Manette A.W. Dinnessen, Otto Visser, Sanne H. Tonino, Marjolein W.M. Poel, Nicole M.A. Blijlevens, Marie José Kersten, Pieternella J. Lugtenburg & Avinash G. Dinmohamed. (2020) The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study. eJHaem 1:2, pages 489-497.
Crossref
Scott J. Sonne, Wen-Shi Shieh, Sunil K. Srivastava & Bradley T. Smith. (2020) Lymphoma masquerading as occlusive retinal vasculitis: A case study. American Journal of Ophthalmology Case Reports 19, pages 100777.
Crossref
Yanan Jiang, Zhaoyi Miao, Jinhuan Wang, Jing Chen, Yangyang Lv, Donghui Xing, Xiaofang Wang, Yafei Wang, Zeng Cao & Zhigang Zhao. (2019) Clinical characteristics and prognosis associated with multiple primary malignant tumors in non-Hodgkin lymphoma patients. Tumori Journal 105:6, pages 474-482.
Crossref
Zhihua Huang, Zhiping Hu, Juan Ouyang & Cheng Huang. (2019) Electroacupuncture regulates the DREAM/NF-κB signalling pathway and ameliorates cyclophosphamide-induced immunosuppression in mice. Acupuncture in Medicine 37:5, pages 292-300.
Crossref
Dongfeng Zeng, Aakash Desai, Fangfang Yan, Tiejun Gong, Haige Ye, Makhdum Ahmed, Krystle Nomie, Jorge Romaguera, Richard Champlin, Shaoying Li & Michael Wang. (2019) Challenges and Opportunities for High-grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangement (Double-hit Lymphoma). American Journal of Clinical Oncology 42:3, pages 304-316.
Crossref
Chong Chyn Chua, Shaun Fleming & Andrew H. Wei. (2019) Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. Best Practice & Research Clinical Haematology 32:1, pages 3-12.
Crossref
Paola Ghione, Federica Cavallo, Carlo Visco, Zhengming Chen, Alessia Castellino, Maria C. Tisi, Irene Dogliotti, Maura Nicolosi, Mario Boccadoro, John P. Leonard, Umberto Vitolo & Peter Martin. (2017) A retrospective study of R‐DHAP/Ox for early progressing follicular lymphoma. British Journal of Haematology 183:5, pages 828-831.
Crossref
Vitaliana De Sanctis, Marco Alfò, Alice Di Rocco, Michela Ansuinelli, Eleonora Russo, Mattia F. Osti, Maurizio Valeriani, Giuseppe Minniti, Lavinia Grapulin, Daniela Musio, Stefano Bracci, Alessandra Spagnoli, Maria Luisa Moleti, Vincenzo Tombolini & Maurizio Martelli. (2017) Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results. Hematological Oncology 35:4, pages 554-560.
Crossref
Emma E van Daalen, Raffaella Rizzo, Andreas Kronbichler, Ron Wolterbeek, Jan A Bruijn, David R Jayne, Ingeborg M Bajema & Chinar Rahmattulla. (2017) Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Annals of the Rheumatic Diseases 76:6, pages 1064-1069.
Crossref
Abdallah Abou Zahr, Ami M. Kavi, Sudipto Mukherjee & Amer M Zeidan. (2017) Therapy-related myelodysplastic syndromes, or are they?. Blood Reviews 31:3, pages 119-128.
Crossref
Laura Magnano, Silvia Montoto, Eva González-Barca, Javier Briones, Juan Manuel Sancho, Ana Muntañola, Antonio Salar, Joan Besalduch, Lourdes Escoda, Carol Moreno, Eva Domingo-Domenech, Cristina Estany, Albert Oriol, Albert Altés, Carmen Pedro, Santiago Gardella, Antoni Asensio, Pilar Vivancos, Alberto Fernández de Sevilla, Josep María Ribera, Dolors Colomer, Elias Campo & Armando López-Guillermo. (2017) Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. Annals of Hematology 96:4, pages 639-646.
Crossref
C. Demoor-Goldschmidt, P. Agape, I. Barillot & M.A. Mahé. (2016) Radiothérapie des lymphomes malins non hodgkiniens ganglionnaires folliculaires et diffus de stade limité. Cancer/Radiothérapie 20:6-7, pages 530-534.
Crossref
V. Martini, L. Marconato, A. Poggi, F. Riondato, L. Aresu, M. Cozzi & S. Comazzi. (2016) Canine small clear cell/T-zone lymphoma: clinical presentation and outcome in a retrospective case series. Veterinary and Comparative Oncology 14, pages 117-126.
Crossref
Sheng-Hsuan Chien, Chia-Jen Liu, Ying-Chung Hong, Chung-Jen Teng, Yu-Wen Hu, Fan-Chen Ku, Chiu-Mei Yeh, Tzeon-Jye Chiou, Jyh-Pyng Gau & Cheng-Hwai Tzeng. (2015) Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study. Journal of Cancer Research and Clinical Oncology 141:11, pages 1995-2004.
Crossref
Clara J.K. LamRochelle E. CurtisGraça M. DoresEric A. EngelsNeil E. CaporasoAaron PolliackJoan L. WarrenHeather A. YoungPaul H. LevineAngelo F. ElmiJoseph F. FraumeniJrJrMargaret A. TuckerLindsay M. Morton. (2015) Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma. Journal of Clinical Oncology 33:28, pages 3096-3104.
Crossref
Lena Specht & Joachim Yahalom. (2015) The concept and evolution of involved site radiation therapy for lymphoma. International Journal of Clinical Oncology 20:5, pages 849-854.
Crossref
MAJA LISIK-HABIB, URSZULA CZERNEK, SYLWIA DĘBSKA-SZMICH, MAGDALENA KRAKOWSKA, JOANNA KUBICKA-WOŁKOWSKA & PIOTR POTEMSKI. (2015) Secondary cancer in a survivor of Hodgkin’s lymphoma: A case report and review of the literature. Oncology Letters 9:2, pages 964-966.
Crossref
Zhengzi Qian, Zheng Song, Huilai Zhang, Xianhuo Wang, Jing Zhao & Huaqing Wang. (2015) Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma. BioMed Research International 2015, pages 1-7.
Crossref
Lindsay M. Morton, Anthony J. Swerdlow, Michael Schaapveld, Safaa Ramadan, David C. Hodgson, John Radford & Flora E. van Leeuwen. (2014) Current knowledge and future research directions in treatment-related second primary malignancies. European Journal of Cancer Supplements 12:1, pages 5-17.
Crossref
Keemo Delos Santos, Lavarnan Sivanathan, Kelly Lien & Urban Emmenegger. 2014. Metronomic Chemotherapy. Metronomic Chemotherapy 119 134 .
Keemo Delos Santos, Kelly Lien, Soley Georgsdottir, Lavarnan Sivanathan & Urban Emmenegger. 2014. Metronomic Chemotherapy. Metronomic Chemotherapy 263 279 .
A Adenis, I Ray-Coquard, A Italiano, E Chauzit, B Bui-Nguyen, J-Y Blay, E Tresch-Bruneel, C Fournier, S Clisant, E Y Amela, P A Cassier, M Molimard & N Penel. (2013) A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours. British Journal of Cancer 109:10, pages 2574-2578.
Crossref
Erion Dobi, Thierry Nguyen, Christophe Borg, Xavier Pivot, Bernard Royer & Stefano Kim. (2013) Treatment-Induced Acute Leukaemia after Major Response to Cyclophosphamide-Based Metronomic Chemotherapy in Refractory Heavily Pre-Treated Prostate Cancer. Journal of Cancer Therapy 04:01, pages 165-169.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.